Drug companies Janssen Pharmaceutical, a subsidiary of Johnson & Johnson, and Bayer Healthcare are being investigated by attorneys for their marketing strategies. For the blood-thinning drug Xarelto (rivaroxaban), these strategies were aimed at putting profits over safety. Even though Xarelto was said to surpass all other drugs of its kind in effectiveness, safety and ease of use, it turned out to be life-threatening for many users.
Xarelto, approved by the FDA in 2011, was prescribed largely to treat and prevent blood clots deep in the body and lungs, as well as atrial fibrillation, or an irregular heart rate. People taking this drug, however, have experienced deadly, irreversible internal bleeding. Xarelto is even more sinister than other blood-thinners because, whereas bleeds caused by Coumadin and warfarin can be reversed with Vitamin K, there is no way to halt the bleeding process caused by Xarelto. Compounding this, the drug companies claimed that Xarelto was easier to use because it did not involve the regular blood-monitoring tests required by other anticoagulants, even though such monitoring has been shown to prevent bleeds. Because they were not monitored by healthcare professionals, people taking this drug were at a far higher risk of suffering from uncontrollable internal bleeding, and were three times more likely to suffer death than people taking Coumadin or warfarin.
Because of the dangers of Xarelto, attorneys have filed lawsuits in a multidistrict litigation against the manufacturers of Xarelto. Multidistrict litigation, or MDL, is different than a class action suit because it treats every case and its injuries individually. The first trial in the MDL is scheduled for Fall 2016 in the Eastern District of Louisiana.
If you or a loved one have experienced the dangerous effects of Xarelto, we may be able to help. The attorneys at The Yost Legal Group are experienced professionals ready to investigate your claim with compassion and determination. For a free consultation, call us at 1-800-YOST-LAW.